Related Experiment Videos
Cerebroprotective effects of a novel pyrazoline derivative, MS-153, on focal ischemia in rats
H Kawazura1, Y Takahashi, Y Shiga
1Institute of Biological Science, Mitsui Pharmaceuticals, Inc., Chiba, Japan.
Abstract:
MS-153 ((R)-(-)-5-methyl-1-nicotinoyl-2-pyrazoline) is a novel pyrazoline compound that has potent cerebroprotective effects in the rat focal cerebral ischemia model. Middle cerebral artery (MCA) occlusion in rats allows detailed assessment of both functional and morphological sequelae of brain infarct. Using this model, we evaluated the cerebroprotective effects of MS-153. Treatment with MS-153 (12.5 mg/kg, i.v. bolus followed by 6.25 mg/kg/hr or 25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 7 days) significantly reduced infarct volumes and improved neurological deficits in MCA occluded rats 7 days after occlusion. Delayed treatment significantly reduced infarct volume 24 hr after MCA occlusion when MS-153 (25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 21 hr) administration was started 3 hr after occlusion. Brain edema was also significantly improved when MS-153 (25.0 mg/kg, i.v. bolus followed by 12.5 mg/kg/hr infusion for 18 hr) administration was started 6 hr after occlusion.
Insights
MS-153, a novel pyrazoline compound, demonstrates significant cerebroprotective effects. It effectively reduces brain infarct volume and improves neurological deficits in a rat model of focal cerebral ischemia.
Area of Science:
- Neuroscience
- Pharmacology
- Cerebrovascular Research
Background:
- Focal cerebral ischemia, such as middle cerebral artery (MCA) occlusion in rats, is a critical model for studying brain infarcts.
- Assessing both functional and morphological outcomes is essential for evaluating potential therapeutic interventions.
Purpose of the Study:
- To evaluate the cerebroprotective effects of the novel pyrazoline compound, MS-153, in a rat model of focal cerebral ischemia.
- To determine the efficacy of MS-153 in reducing infarct volume, improving neurological deficits, and mitigating brain edema.
Main Methods:
- Utilized the rat middle cerebral artery (MCA) occlusion model to induce focal cerebral ischemia.
- Administered MS-153 intravenously at varying doses and infusion rates for different durations.
- Assessed infarct volumes, neurological deficits, and brain edema at specified time points post-occlusion.
Main Results:
- MS-153 treatment significantly reduced infarct volumes and improved neurological deficits in MCA-occluded rats 7 days after occlusion.
- Delayed administration of MS-153 (started 3 hours post-occlusion) significantly reduced infarct volume 24 hours after MCA occlusion.
- Delayed MS-153 administration (started 6 hours post-occlusion) significantly improved brain edema.
Conclusions:
- MS-153 exhibits potent cerebroprotective properties in a rat model of focal cerebral ischemia.
- The compound demonstrates efficacy in reducing brain infarcts, improving functional outcomes, and decreasing edema, even with delayed treatment.
- MS-153 represents a promising therapeutic candidate for managing ischemic stroke.